0000000000903245

AUTHOR

Jeffrey Lipman

showing 7 related works from this author

Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic an…

2016

Objectives: We utilized the database of the Defining Antibiotic Levels in Intensive care unit patients (DALI) study to statistically compare the pharmacokinetic/pharmacodynamic and clinical outcomes between prolonged- infusion and intermittent-bolus dosing of piperacillin/tazobactam and meropenem in critically ill patients using inclusion criteria similar to those used in previous prospective studies. Methods: This was a post hoc analysis of a prospective, multicentre pharmacokinetic point-prevalence study (DALI), which recruited a large cohort of critically ill patients from 68 ICUs across 10 countries. Results: Of the 211 patients receiving piperacillin/tazobactam and meropenem in the DAL…

0301 basic medicineMalePenicillanic Acidintensive care unitlaw.inventionthienamycin derivative abdominal infection[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseaseslawcentral nervous system infectioncreatinine clearancePharmacology (medical)Infusions IntravenouProspective StudiesInfusions IntravenousProspective cohort studyTazobactam Drug CombinationAged; Anti-Bacterial Agents; Blood Chemical Analysis; Critical Illness; Female; Humans; Infusions Intravenous; Intensive Care Units; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin Tazobactam Drug Combination; Prospective Studies; Thienamycins; Treatment Outcome; Pharmacology; Microbiology (medical); Pharmacology (medical); Infectious Diseasescritical illneMicrobial Sensitivity TestadultRespiratory infectionclinical trialMiddle Agedcontinuous infusionanalogs and derivativeIntensive care unit3. Good healthAnti-Bacterial Agentsantiinfective agentintravenous drug administrationIntensive Care Units[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyTreatment OutcomeInfectious DiseasesPiperacillin/tazobactammulticenter study (topic)SOFA scoreFemaletreatment outcome AgedIntravenousprospective studyHumanmedicine.drugsurvival rateMicrobiology (medical)medicine.medical_specialtyInfusionspost hoc analysirespiratory tract infectionCritical IllnessAged; Anti-Bacterial Agents; Blood Chemical Analysis; Critical Illness; Female; Humans; Infusions Intravenous; Intensive Care Units; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Prospective Studies; Thienamycins; Treatment Outcome; Pharmacology; Pharmacology (medical); Infectious Diseases030106 microbiologybloodstream infectionMicrobial Sensitivity Testsminimum inhibitory concentrationpiperacillin plus tazobactamMeropenemTazobactamArticle03 medical and health sciencescritically ill patientInternal medicineAnti-Bacterial AgentmedicineSequential Organ Failure Assessment ScoreHumansThienamycinsurvival timeblood analysiAgedPiperacillinPharmacologybusiness.industryBlood Chemical AnalysiMeropenemmajor clinical studySurgeryProspective Studiemulticenter studyPharmacology; Pharmacology (medical); Infectious Diseases[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/PharmacologyThienamycinspiperacillin tazobactam drug combinationurinary tract infectionbusinessBlood Chemical AnalysisPiperacillin
researchProduct

Poor timing and failure of source control are risk factors for mortality in critically ill patients with secondary peritonitis

2022

PURPOSE: To describe data on epidemiology, microbiology, clinical characteristics and outcome of adult patients admitted in the intensive care unit (ICU) with secondary peritonitis, with special emphasis on antimicrobial therapy and source control. METHODS: Post hoc analysis of a multicenter observational study (Abdominal Sepsis Study, AbSeS) including 2621 adult ICU patients with intra-abdominal infection in 306 ICUs from 42 countries. Time-till-source control intervention was calculated as from time of diagnosis and classified into 'emergency' ( 6 h). Relationships were assessed by logistic regression analysis and reported as odds ratios (OR) and 95% confidence interval (CI). RESULTS: The…

AdultSecondary peritonitiCritical IllnessPeritonitisCritical Care and Intensive Care MedicineAnti-Bacterial AgentsAntimicrobial therapyIntensive Care UnitsSecondary peritonitisIntra-abdominal infectionAnti-Infective AgentsRisk FactorsSource controlSepsisMedicine and Health SciencesHumansIntraabdominal InfectionsMortalityRetrospective StudiesAntimicrobial therapy; Intra-abdominal infection; Mortality; Secondary peritonitis; Source controlIntensive Care Medicine
researchProduct

Abdominal infections in the intensive care unit: characteristics, treatment and determinants of outcome

2014

Background: Abdominal infections are frequent causes of sepsis and septic shock in the intensive care unit (ICU) and are associated with adverse outcomes. We analyzed the characteristics, treatments and outcome of ICU patients with abdominal infections using data extracted from a one-day point prevalence study, the Extended Prevalence of Infection in the ICU (EPIC) II.Methods: EPIC II included 13,796 adult patients from 1,265 ICUs in 75 countries. Infection was defined using the International Sepsis Forum criteria. Microbiological analyses were performed locally. Participating ICUs provided patient follow-up until hospital discharge or for 60 days.Results: Of the 7,087 infected patients, 1,…

Malehumanoslnfectious Diseases and Global Health Radboud Institute for Molecular Life Sciences [Radboudumc 4]Settore MED/41 - AnestesiologiaGUIDELINESlaw.inventionsepsislawAbdomenabdominal infections; crtitical carePrevalenceMedicine and Health SciencesMedicinePathologie maladies infectieusesAbdomen; Adult; Aged; Anti-Bacterial Agents; Bacterial Infections; Critical Illness; Cross-Sectional Studies; Female; Humans; Male; Middle Aged; Prevalence; Sepsis; Treatment Outcome; Young Adult; Intensive Care Units; Infectious Diseasesmediana edadMedicine(all)ancianoAbdominal Infection Sepsis Epic IIresultado del tratamientoprevalenciaBacterial InfectionsMiddle AgedadultoAbdominal infectionIntensive care unitAbscessAnti-Bacterial AgentsPREVALENCEadulto jovenIntensive Care UnitsTreatment OutcomeInfectious Diseasesmedicine.anatomical_structureSAPS IIAbdominal infection ; Abscess ; Peritonitis ; Severe sepsis ; Critical care ; Antibiotic therapy ; MicrobiologyFemaleSOFA score10023 Institute of Intensive Care MedicineantibacterianosResearch ArticleAdultmedicine.medical_specialtyCritical Illnessunidades de cuidados intensivosenfermedad críticaPeritonitis610 Medicine & healthNOSOCOMIAL INTRAABDOMINAL INFECTIONSPeritonitisMicrobiologySepsisYoung AdultMORBIDITYInternal medicineMANAGEMENTHumansAgedCANDIDASEPSISbusiness.industrySeptic shockMORTALITYAbdominal InfectionADULTS2725 Infectious DiseasesAntibiotic therapymedicine.diseaseSevere sepsisSurgeryCritical careCross-Sectional Studiesinfecciones bacterianasAbdomenbusinessestudios transversales
researchProduct

Epidemiology and outcomes of hospital-acquired bloodstream infections in intensive care unit patients: the EUROBACT-2 international cohort study.

2023

Purpose: In the critically ill, hospital-acquired bloodstream infections (HA-BSI) are associated with significant mortality. Granular data are required for optimizing management, and developing guidelines and clinical trials. Methods: We carried out a prospective international cohort study of adult patients (≥ 18 years of age) with HA-BSI treated in intensive care units (ICUs) between June 2019 and February 2021. Results: 2600 patients from 333 ICUs in 52 countries were included. 78% HA-BSI were ICU-acquired. Median Sequential Organ Failure Assessment (SOFA) score was 8 [IQR 5; 11] at HA-BSI diagnosis. Most frequent sources of infection included pneumonia (26.7%) and intravascular catheters…

antibiotic resistancebloodstream infectionhospital-acquiredbacteremiaCritical Care and Intensive Care Medicineantibiotic resistance ; bacteremia ; bloodstream infection ; hospital-acquired.
researchProduct

Antimicrobial de-escalation in the critically ill patient and assessment of clinical cure : the DIANA study

2020

© 2020 The Author(s).

OriginalDELPHI METHODCritical Care and Intensive Care MedicineGUIDELINESlaw.invention0302 clinical medicineAnti-Infective Agents[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseaseslawEpidemiologyMedicine and Health SciencesAntimicrobial de-escalationEPIDEMIOLOGYComputingMilieux_MISCELLANEOUS[SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseasesVentilator-associated pneumoniaIntensive care unitAnti-Bacterial Agents3. Good healthIntensive Care UnitsSTEWARDSHIP PROGRAM[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/VirologyCohortAntimicrobial de-escalation; Bacterial infection; Clinical cure; Empirical therapy; Intensive care unit;Clinical cureAntimicrobial de-escalation; Bacterial infection; Clinical cure; Empirical therapy; Intensive care unitAdultmedicine.medical_specialtyCombination therapyCritical IllnessANTIBIOTIC-THERAPYNO03 medical and health sciences[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemBETA-LACTAMInternal medicineSettore MED/41 - ANESTESIOLOGIAmedicineHumans[SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/ParasitologyIntensive care unitVENTILATOR-ASSOCIATED PNEUMONIAbusiness.industrySEPTIC SHOCKR-PACKAGEbacterial infectionIntensive care unit.030208 emergency & critical care medicinemedicine.disease[SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/BacteriologyEmpirical therapyDiscontinuationSEVERE SEPSISlnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4]Carbapenems030228 respiratory systemRelative riskBacterial infectionbusinessDe-escalation
researchProduct

Different epidemiology of bloodstream infections in COVID-19 compared to non-COVID-19 critically ill patients: a descriptive analysis of the Eurobact…

2022

Funder: European society of Intensive Care Medicine

Malebloodstream infections:Other subheadings::Other subheadings::/epidemiology [Other subheadings]Critical IllnessCOVID-19 (Malaltia) - EpidemiologiaRESISTANT ENTEROCOCCIBacteremiaBloodstream infectionCritical Care and Intensive Care Medicine:Pathological Conditions Signs and Symptoms::Pathologic Processes::Disease Attributes::Critical Illness [DISEASES]Cohort Studies:afecciones patológicas signos y síntomas::procesos patológicos::atributos de la enfermedad::enfermedad crítica [ENFERMEDADES]Sepsis:virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES]Medicine and Health SciencesHumansNCT03937245Unitats de cures intensivesAgedCross InfectionMalalties bacterianes:infecciones bacterianas y micosis::infección::infección hospitalaria [ENFERMEDADES]Research:Otros calificadores::Otros calificadores::/epidemiología [Otros calificadores]Bacteremia; Bloodstream infection; COVID-19; Enterococcus; ICU-acquiredCOVID-19:Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES]:Bacterial Infections and Mycoses::Infection::Cross Infection [DISEASES]Intensive Care UnitsNCTICURNAICU-acquiredEnterococcus
researchProduct

Antimicrobial Lessons From a Large Observational Cohort on Intra-abdominal Infections in Intensive Care Units

2021

Severe intra-abdominal infection commonly requires intensive care. Mortality is high and is mainly determined by disease-specific characteristics, i.e. setting of infection onset, anatomical barrier disruption, and severity of disease expression. Recent observations revealed that antimicrobial resistance appears equally common in community-acquired and late-onset hospital-acquired infection. This challenges basic principles in anti-infective therapy guidelines, including the paradigm that pathogens involved in community-acquired infection are covered by standard empiric antimicrobial regimens, and second, the concept of nosocomial acquisition as the main driver for resistance involvement. I…

Drug Resistancemedicine.disease_causeSeverity of Illness Indexlaw.invention0302 clinical medicineENTEROBACTERIACEAElawDrug Resistance Multiple BacterialMedicine and Health SciencesPharmacology (medical)Cross InfectionbiologyBacterialAntimicrobialIntensive care unitAnti-Bacterial AgentsCommunity-Acquired InfectionsEuropeIntensive Care UnitsAnti-Bacterial Agents; Community-Acquired Infections; Critical Illness; Cross Infection; Europe; Humans; Intensive Care Units; Intraabdominal Infections; Microbial Sensitivity Tests; Peritonitis; Sepsis; Severity of Illness Index; Drug Resistance Multiple BacterialESCHERICHIA-COLI030220 oncology & carcinogenesisKLEBSIELLA-PNEUMONIAEBLOOD-STREAM INFECTIONSPYELONEPHRITISMultiplemedicine.medical_specialtyCritical IllnessMicrobial Sensitivity TestsPeritonitisEnterococcus faecalisNO03 medical and health sciencesIntra‑abdominal InfectionsAntibiotic resistanceFOODSepsisIntensive careInternal medicinemedicineHumansFLUOROQUINOLONE RESISTANCEPseudomonas aeruginosabusiness.industrySeptic shockMORTALITYbiology.organism_classificationmedicine.diseaseRISK-FACTORSIntraabdominal Infectionsbusiness030217 neurology & neurosurgeryEnterococcus faecium
researchProduct